Eli Lil­ly antes up $60M gam­ble on a dis­cov­ery deal with GSK-backed biotech

GSK-backed Sit­ryx has scored an­oth­er il­lus­tri­ous part­ner: Eli Lil­ly.

The Ox­ford, UK-based com­pa­ny, which is fo­cused on reg­u­lat­ing im­mune cell me­tab­o­lism to treat can­cer and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER